- Home
- SSMR vs GHRS Comparison
SSMR vs GHRS Comparison
Compare SSMR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSMR | GHRS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SSMR | GHRS |
|---|---|---|
| Price | $12.36 | $20.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $19.17 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 534.5K | 295.9K |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $12.04 |
| 52 Week High | $19.61 | $31.44 |
Technical Indicators
Market Signals| Indicator | SSMR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 47.43 |
| Support Level | $11.38 | $19.75 |
| Resistance Level | $15.33 | $22.88 |
| Average True Range (ATR) | 1.01 | 1.12 |
| MACD | 0.11 | 0.53 |
| Stochastic Oscillator | 31.45 | 70.15 |
Price Performance
Historical ComparisonAbout SSMR Sunshine Silver Mining & Refining Company Common Stock
Sunshine Silver Mining & Refining Co is a mining exploration and development company. It owns and develops the Sunshine Mine, the Sunshine Silver/Copper Refinery, and related facilities, including the Sunshine Tailings Storage Facility and historical antimony refinery grounds. The Sunshine Mine is a permitted past-producing silver mine in the United States that has historically produced silver, antimony, copper, and lead.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.